Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 versus insulin glargine in insulin naïve type 2 diabetes patients: Cost-effectiveness analysis in the UK setting

Current Medical Research and Opinion

Volumn 21, Issue 12, 2005, Pages 2063-2071

  Valentine, William J ^a   Palmer, Andrew J ^a   Lammert, Morten ^b   Nicklasson, Lars ^c   Foos, Volker ^a   Roze, Stéphane ^a  

^a IQVIA   (United States)

^b NOVO NORDISK A S   (Denmark)

^c NOVO NORDISK INC   (United States)

Author keywords

Biphasic insulin aspart; Cost effectiveness; Costs; Insulin glargine; Modeling; UK

Indexed keywords

HEMOGLOBIN A1C; INSULIN ASPART; INSULIN GLARGINE; ORAL ANTIDIABETIC AGENT;

ADULT; ARTICLE; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; DISEASE SIMULATION; DRUG COST; EVALUATION; FEMALE; HEALTH CARE FINANCING; HUMAN; INFUSION PUMP; LIFE EXPECTANCY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOMES RESEARCH; PEER REVIEW; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; TREATMENT FAILURE; TREATMENT OUTCOME; VALIDATION PROCESS;

ADULT; AGED; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; FEMALE; HEALTH CARE COSTS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; LIFE EXPECTANCY; MALE; MIDDLE AGED;

EID: 29144462668     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079905X74989     Document Type: Article

References (32)

1. UKPDS Group. Intensive blood-glucose control with ulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53
2. Wright A, Burden AC, Paisey RB, et al. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective diabetes study (UKPDS 57). Diabetes Care 2002;25:330-6
3. Riddle MC, Rosenstock J, Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003;26:3080-6
4. Kilo C, Mezitis N, Jain R, et al. Starting patients with type 2 diabetes on insulin therapy using once-daily injections of biphasic insulin aspart 70/30, biphasic human insulin 70/30, or NPH insulin in combination with metformin. J Diabetes Complications 2003;17:307-13
5. McSorley PT, Bell PM, Jacobsen LV, et al. Twice-daily biphasic insulin aspart 30 versus biphasic human insulin 30: a double-blind crossover study in adults with type 2 diabetes mellitus. Clin Ther 2002;24:530-9
6. Boehm BO, Home PD, Behrend C, et al. Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: a randomized trial in Type 1 and Type 2 diabetic patients. Diabet Med 2002;19:393-9
7. Lindholm A, McEwen J, Riis AP. Improved postprandial glycemic control with insulin aspart. A randomized double-blind cross-over trial in type 1 diabetes. Diabetes Care 1999;22:801-5
8. Raskin P, Allen E, Hollander P, et al. INITIATE Study Group. Initiating insulin therapy in type 2 diabetes: A comparison of biphasic and basal insulin analogs. Diabetes Care 2005;28:260-5
9. Palmer AJ, Roze S, Valentine W, et al. The CORE Diabetes Model: Projecting long term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision making. Curr Med Res Opin 2004;20(Suppl 1):S6-26
10. Palmer AJ, Roze S, Valentine W, et al. Validation of the CORE Diabetes Model against epidemiological and clinical studies. Curr Med Res Opin 2004;20(Suppl 1):S27-40
11. UKPDS Group. UK prospective diabetes study 16. Overview of 6 years therapy of type II diabetes: a progressive disease. Diabetes 1995;44:1249-58
12. Second National Health and Nutrition Examination Survey (NHANES II) Public-Use Data Files. Available from: www.cdc. gov/nchs/products/elec_prods/ subject/nhanesii.htm [Accessed 6 Sept 2005]
13. Clarke P, Gray A, Legood R, et al. The impact of diabetes-related complications on healthcare costs: results from the United Kingdom Prospective Diabetes Study (UKPDS study no. 65). Diabet Med 2003;20:442-50
14. Department of Health. NHS reference costs 2003 and national tariff 2004. Available from: www.dh.gov.uk/Publ icationsAndStatistics/Publications/ PublicationsPolicyAndGuida nce/PublicationsPolicyAndGuidanceArticle/fs/en? CONTENT_ ID=4070195&chk=UzhHA3 [Accessed 6 Sept 2005]
15. Netten A, Curtis L. Unit costs of health and social care 2003. Available from: www.pssru.ac.uk/pdf/uc2003/uc2003_inflation. pdf [Accessed 6 Sept 2005]
16. Monthly Index of Marketed Medicines, November 2004. Available from: www.emims.com [Accessed 6 Sept 2005]
17. Briggs AH, Wonderling DE, Mooney CZ. Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation. Health Econ 1997;6:327-40
18. Devlin N, Parkin D. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ 2004;13:437-52
19. National Institute for Clinical Excellence. Clinical guideline G - management of type 2 diabetes. September 2002. Available from http://www.nice.org.uk/pdf/NICE_INHERITEG_guidelines. pdf [Accessed 6 Sept 2005]
20. Malone JK, Beattie SD, Campaigne BN, et al. Therapy after single oral agent failure: adding a second oral agent or an insulin mixture? Diabetes Res Clin Pract 2003;62:187-95
21. Hermansen K, Fontaine P, Kukolja KK, et al. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes. Diabetologia 2004;47:622-9
22. Primatesta P, Poulter NR. Lipid levels and the use of lipid-lowering agents in England and Scotland. Eur J Cardiovasc Prev Rehabil 2004;11:484-8
23. Wilson A, Baker R, Thompson J, et al. Coverage in screening for diabetic retinopathy according to screening provision: results from a national survey in England and Wales. Diabet Med 2004;21:271-8
24. Benett IJ, Lambert C, Hinds G, et al. Emerging standards for diabetes care from a city-wide primary care audit. Diabet Med 1994;11:489-92
25. Currie CJ, Morgan CL, Peters JR. The epidemiology and cost of inpatient care for peripheral vascular disease, infection, neuropathy, and ulceration in diabetes. Diabetes Care 1998;21:42-8
26. United Kingdom Prospective Diabetes Study Group. Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40. BMJ 1998;317:720-6
27. NHS UK transplant statistics, 2002. Available from www. uktransplant.org.uk/ukt/statistics/statistics.jsp [Accessed 6 Sept 2005]
28. Ghatnekar O, Persson U, Willis M, et al. Cost effectiveness of becaplermin in the treatment of diabetic foot ulcers in four European countries. Pharmacoeconomics 2001;19:767-78
29. Leese GP, Wang J, Broomhall J, et al. Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes: a population-based study of health service resource use. Diabetes Care 2003;26:1176-80
30. Scuffham P, Carr L. The cost-effectiveness of continuous subcutaneous insulin infusion compared with multiple daily injections for the management of diabetes. Diabet Med 2003;20:586-93
31. James M, Turner DA, Broadbent DM, et al. Cost effectiveness analysis of screening for sight threatening diabetic eye disease. BMJ 2000;320:1627-31
32. OMNILABS (UK) Limited, price list. London, 2000